Loreto Martinez-Gonzalez - JoVE Visualize

Showing results (11-20 of 19) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 19 results.

Neurobiology of Disease|February 7, 2024

Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosisEva P Cuevas, Loreto Martinez-Gonzalez, Clara Gordillo, et al.

Colloids and Surfaces. B, Biointerfaces|May 20, 2026

Nanotechnology-based encapsulation of neflamapimod: A new therapeutic strategy for lewy body dementiaMaria Paz García-Simarro, Nuria Genicio, Manuel Bañobre-López, et al.

ACS Chemical Neuroscience|July 15, 2020

Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson's DiseaseRita Maria Concetta Di Martino, Letizia Pruccoli, Alessandra Bisi, et al.

European Journal of Medicinal Chemistry|November 3, 2020

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosisElisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, et al.

Journal of Medicinal Chemistry|January 8, 2025

Modulation of Mitochondria-Endoplasmic Reticulum Contacts (MERCs) by Small Molecules as a New Strategy for Restoring Lipid Metabolism in an Amyotrophic Lateral Sclerosis ModelMikel Etxebeste-Mitxeltorena, Hector Flores-Romero, Sandra Ramos-Inza, et al.

Neuropharmacology|December 13, 2025

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyMarta Gomez-Almeria, Loreto Martinez-Gonzalez, Ana Teresa Matos, et al.

Journal of Medicinal Chemistry|April 8, 2025

Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular ModelsThomas D Emmerich, Eleanor J Taylor-Chilton, Elena Caballero, et al.

Journal of Medicinal Chemistry|August 7, 2018

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation InhibitorsAnnachiara Gandini, Manuela Bartolini, Daniele Tedesco, et al.

ACS Chemical Neuroscience|August 6, 2025

Design, Synthesis and Biological Evaluation of Chromeno[3,4-b]xanthones as Multifunctional Agents for Alzheimer's DiseaseDaniela Malafaia, Natércia F Brás, Anna Sampietro, et al.

Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 19 results.

Neurobiology of Disease|February 7, 2024

Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosisEva P Cuevas, Loreto Martinez-Gonzalez, Clara Gordillo, et al.

Colloids and Surfaces. B, Biointerfaces|May 20, 2026

Nanotechnology-based encapsulation of neflamapimod: A new therapeutic strategy for lewy body dementiaMaria Paz García-Simarro, Nuria Genicio, Manuel Bañobre-López, et al.

ACS Chemical Neuroscience|July 15, 2020

Novel Curcumin-Diethyl Fumarate Hybrid as a Dualistic GSK-3β Inhibitor/Nrf2 Inducer for the Treatment of Parkinson's DiseaseRita Maria Concetta Di Martino, Letizia Pruccoli, Alessandra Bisi, et al.

European Journal of Medicinal Chemistry|November 3, 2020

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosisElisa Rojas-Prats, Loreto Martinez-Gonzalez, Claudia Gonzalo-Consuegra, et al.

Journal of Medicinal Chemistry|January 8, 2025

Modulation of Mitochondria-Endoplasmic Reticulum Contacts (MERCs) by Small Molecules as a New Strategy for Restoring Lipid Metabolism in an Amyotrophic Lateral Sclerosis ModelMikel Etxebeste-Mitxeltorena, Hector Flores-Romero, Sandra Ramos-Inza, et al.

Neuropharmacology|December 13, 2025

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyMarta Gomez-Almeria, Loreto Martinez-Gonzalez, Ana Teresa Matos, et al.

Journal of Medicinal Chemistry|April 8, 2025

Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular ModelsThomas D Emmerich, Eleanor J Taylor-Chilton, Elena Caballero, et al.

Journal of Medicinal Chemistry|August 7, 2018

Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation InhibitorsAnnachiara Gandini, Manuela Bartolini, Daniele Tedesco, et al.

ACS Chemical Neuroscience|August 6, 2025

Design, Synthesis and Biological Evaluation of Chromeno[3,4-b]xanthones as Multifunctional Agents for Alzheimer's DiseaseDaniela Malafaia, Natércia F Brás, Anna Sampietro, et al.

Pageof 2